1262036-50-9

Basic information

• Product Name: LY2886721
• Synonyms: LY2886721;N-[3-[(4aS,7aS)-2-Amino-4a,5-dihydro-4H-furo[3,4-d][1,3]thiazin-7a(7H)-yl]-4-fluorophenyl]-5-fluoro-2-pyridinecarboxamide;N-(3-((4aS,7aS)-2-aMino-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl)-5-fluoropicolinaMide;LY2886721/LY-2886721;LY2886721 HCL SALT;LY2886721HCL;N-[3-[(4aS,7aS)-2-Amino-4a,5-dihydro-4H-furo[3,4-d][1,3]thiazin-7a(7H)-yl]-4-fluorophenyl]-5-fluoro-2-pyridinecarboxamide LY2886721;LY2886721, >=98%
• CAS NO: 1262036-50-9
• Molecular Formula: C₁₈H₁₆F₂N₄O₂S
• Molecular Weight: 390.41
• Product Categories: Inhibitors
• Mol File: 1262036-50-9.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• Density: 1.57
• Solubility: insoluble in H2O; insoluble in EtOH; ≥19.52 mg/mL in DMSO
• PKA: 10.08±0.70(Predicted)
• CAS DataBase Reference: LY2886721(CAS DataBase Reference)
• NIST Chemistry Reference: LY2886721(1262036-50-9)
• EPA Substance Registry System: LY2886721(1262036-50-9)

Safety Data

• Hazardous Substances Data: 1262036-50-9(Hazardous Substances Data)

Usage

Uses

LY2886721 is a BACE inhibitor used to treat Alzheimer's disease.

Biological Activity

ly2886721 is an oral and furothiazine-based inhibitor of β site-amyloid protein cleaving enzyme (bace) with ic50 of 20.3nm. this product has the potency for the treatment of alzheimer's disease.bace, also known as beta-secretase 1, is an aspartic-acid protease that plays important role in the formation of myelin sheaths in peripheral nerve cells.in pdapp mice, oral administration of ly2886721 resulted in a reduction in brain aβ, c99 and sappβ in a dose-dependent pattern 2. aβ levels in the brain were decreased by 20% -65% as compared with the vehicle-treated groups 3 hours after treatment of ly2886721 at a dosage of 3-30 mg/kg per mice. in addition, ly2886721 significantly lowers plasma and csf aβs in the mad study 1.

in vitro

treatment of ly2886721 leads to the inhibition of aβ in hek293swe with ic50 of 18.7nm and pdapp neuronal culture with ic50 10.7 nm1. ly2886721 decreases csf sappβ and increases csf sappα in a dose- dependent manner 2.

references

1. vassar r. bace1 inhibitor drugs in

Upstream product

• 107504-08-5 5-fluoropicolinic acid 
• 717871-83-5 5-fluoropicolinoyl chloride 
• 1262036-49-6 N-(3-((4aS,7aS)-2-Amino-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl)-5-fluoropicolinamide hydrochloride 
• 1262037-71-7 N-(3-((4aS,7aS)-2-benzamido-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl)-5-fluoropicolinamide 

Downstream Products

• 1262036-49-6 N-(3-((4aS,7aS)-2-Amino-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl)-5-fluoropicolinamide hydrochloride 

Relevant articles and documents

Synthesis of BACE Inhibitor LY2886721. Part II. Isoxazolidines as Precursors to Chiral Aminothiazines, Selective Peptide Coupling, and a Controlled Reactive Crystallization

An efficient synthesis of LY2886721 (1) in five steps and 46% overall yield from the chiral nitrone cycloadduct 2 is presented. Minimizing formation of a des-fluoro impurity during hydrogenolysis to cleave the isoxazolidine ring and remove the benzyl chir